In­vest­ing in the time of coro­n­avirus: the good, the bad and the hope­ful, as biotech VC firms close funds worth $3B

Apart from dis­rupt­ing bio­phar­ma R&D and reg­u­la­to­ry time­lines, the coro­n­avirus pan­dem­ic has in­evitably rav­aged fi­nan­cial mar­kets and erod­ed in­vestor risk ap­petite. In­vest­ing in the time of coro­n­avirus feels reck­less, but if biotech ven­ture funds are any in­di­ca­tion, the time is ripe.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER